Regeneron, Sanofi : Dupixent Hits Main Endpoints in Prurigo Nodularis Trial

By Colin Kellaher

Regeneron Pharmaceuticals Inc. and Sanofi SA on Friday said a Phase 3 study of their blockbuster eczema drug Dupixent in the chronic skin condition prurigo nodularis met its primary and all secondary endpoints.

The companies said Dupixent significantly reduced itch at 12 weeks, while nearly three times as many Dupixent patients experienced reductions in both itch and skin lesions at 24 weeks compared to placebo.

Regeneron and Sanofi said prurigo nodularis is the sixth disease where Dupixent has shown positive Phase 3 results, adding that they plan to begin regulatory submissions next year.

Regeneron, of Tarrytown, N.Y., created Dupixent and markets it jointly in the U.S. with France's Sanofi under a 2007 collaboration agreement. Sanofi markets the product internationally.

Write to Colin Kellaher at [e-mail]

(END) Dow Jones Newswires

10-22-21 0624ET